Prostatype Genomics AB (publ) provided sales guidance for the year 2022. Sales in 2022 are estimated to amount to SEK 700,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.027 SEK | -5.26% | +10.20% | -71.58% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-71.58% | 2.52M | |
-18.02% | 8.43B | |
+69.46% | 4.35B | |
+7.88% | 2.78B | |
-1.93% | 2.64B | |
-14.28% | 1.77B | |
-56.54% | 1.74B | |
-16.69% | 1.48B | |
+17.87% | 1.22B | |
-49.60% | 1.02B |
- Stock Market
- Equities
- PROGEN Stock
- News Prostatype Genomics AB
- Prostatype Genomics AB Provides Sales Guidance for the Year 2022